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MaAlthough implantable cardioverter-deﬁbrillators (ICDs) are frequently viewed as a lifelong commitment in that patients
are routinely scheduled for generator exchange (GE) at end of battery life, several considerations should prompt a
reevaluation of risks and beneﬁts before GE. Compared with initial ICD implant, patients receiving replacement devices
are older, and have more comorbidities and shorter life expectancy, all of which may limit the beneﬁt of ICD therapy
following GE. Additionally, GE is associated with signiﬁcant complications, including infection, which may increase the
risk of mortality. In this paper, we review recent data regarding opportunities for risk stratiﬁcation before GE, with a
particular focus on those with improved left ventricular function and those who have not experienced ICD therapies
during the ﬁrst battery life. We also provide a broader perspective on ICD therapy, focusing on how decisions regarding
GE may affect goals of care at the end of life. (J Am Coll Cardiol 2016;67:435–44) © 2016 by the American College of
Cardiology Foundation.I mplantable cardioverter-deﬁbrillator (ICD) ther-apy is associated with signiﬁcant reductions inall-cause mortality among appropriately selected
patients at heightened risk of sudden cardiac death
(SCD) resulting from ventricular arrhythmia (VA).
The decision to implant an ICD is complex, taking
into account the risk of SCD/VA, along with noncar-
diac comorbidities and overall life expectancy. How-
ever, several large, randomized clinical trials have
been performed to assess the efﬁcacy of ICD implan-
tation in both primary and secondary prevention of
SCD/VA. These studies serve as the foundation for
the American College of Cardiology Foundation/
American Heart Association/Heart Rhythm Society
guidelines on ICD implantation (1) and, in conjunc-
tion with large registry studies assessing the safety
and risks associated with ICD implantation (2,3), pro-
vide the basis for patients and providers to have anm the aCardiology Division, Section of Cardiac Electrophysiology, Dep
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More than 100,000 ICDs are implanted annually
in the United States, of which approximately three-
quarters are new device implants and about one-
quarter are generator exchanges (GEs) for end of
battery life (4). Whereas a robust body of literature
exists to support informed decisionmaking at the time
of initial ICD implant, there is a relative paucity of
data to support decision making at the end of battery
life. ICD therapy is frequently viewed as a lifelong
commitment in that patients are scheduled for GE as
a matter of course at the end of battery life. However,
several important considerations should prompt
a reevaluation of risks and beneﬁts to ongoing ICD
therapy before GE. First, compared with pa-
tients undergoing initial ICD implantation, those re-
ceiving replacement devices are older, have moreartment of Medicine, Emory University School of
r, Department of Veterans Affairs, Atlanta, Georgia;
y, Atlanta, Georgia. The authors have reported that
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ABBR EV I A T I ON S
AND ACRONYMS
AF = atrial ﬁbrillation
CRT-D = cardiac
resynchronization therapy-
deﬁbrillator
CRT-P = cardiac
resynchronization therapy-
pacemaker
GE = generator exchange
ICD = implantable
cardioverter-deﬁbrillator
LV = left ventricular
LVEF = left ventricular ejection
fraction
SCD = sudden cardiac death
VA = ventricular arrhythmia
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436comorbidities, and have shorter life expec-
tancy (5,6). This raises the possibility that, as
competing risks of nonarrhythmic death
accrue, the potential beneﬁt of ICD therapy
may be diminished among those undergoing
GE compared with those undergoing initial
implant. Additionally, although GE is gener-
ally considered a relatively straightforward
procedure, elective ICDGE is associatedwith a
major complication rate of approximately 4%
(7), and the occurrence ofmajor complications
in this setting may be associated with an
increased risk formortality (8). In light of these
considerations, the risk/beneﬁt ratio of elec-
tive GE may be very different than that at the
time of initial ICD implant. However, there is a
paucity of data on outcomes and beneﬁts toongoing ICD therapyafterGE,which signiﬁcantly limits
the ability of patients and providers to have an
informed discussion.
OPPORTUNITIES FOR RISK
(RE)-STRATIFICATION AT THE TIME OF GE
IMPROVED VERSUS PERSISTENTLY IMPAIRED LEFT
VENTRICULAR SYSTOLIC FUNCTION. In this coun-
try, most ICDs are implanted for primary preven-
tion, that is, in patients with impaired left
ventricular ejection fraction (LVEF), but without a
history of documented SCD/VA. Therefore, the
mean LVEF at the time of initial ICD implant
(n ¼ 359,993) for all devices implanted between
2005 and 2010 in the National Cardiovascular Data
Registry was 27.7  10.8% (5). In contrast, among
patients in the same registry undergoing ICD GE
(n ¼ 103,985), mean LVEF was signiﬁcantly higher,
at 32.6  13.7%. This ﬁnding highlights that some
patients who undergo initial ICD implant for
impaired LVEF (i.e., #35%) (1) may have improve-
ment in ventricular function between the time of
initial implant and GE. There is a well-established
relationship between lower LVEF and higher risk
of SCD/VA, and the seminal trials establishing the
efﬁcacy of primary prevention ICD therapy (9,10)
were designed, in part, on the basis of this rela-
tionship. Therefore, it is conceivable that an
improvement in LVEF between initial implant and
GE may alter the risk of SCD/VA, such that the risk
of arrhythmic death is no longer sufﬁciently high to
warrant ongoing ICD therapy.
Several studies have looked at outcomes after GE
as a function of improvement in LVEF. In a recent
study in a Veterans Affairs cohort of 231 patients
undergoing GE who were initially implanted forprimary prevention, ongoing ICD therapy was
considered no longer indicated at the time of GE in
59 patients (26%) on the basis of LVEF improvement
to $40% and never having received appropriate ICD
therapy during the ﬁrst battery life (i.e., an “un-
eventful” ﬁrst battery life) (11). Mean LVEF at the
time of GE among those in whom ICD therapy was
considered no longer indicated was 49  9% versus
25  11% among those with persistently impaired LV
function. Importantly, all patients in this cohort
underwent GE. During a mean follow-up of 3.5  2.0
years after GE, the incidence of appropriate ICD
therapy among those in whom ICD therapy was
considered no longer indicated was 2.8%/person-
year, compared with 10.7%/person-year in those in
whom ongoing ICD therapy was considered indi-
cated (p < 0.001). These ﬁndings highlight the
signiﬁcantly lower risk of SCD/VA among those with
improved LVEF and uneventful ﬁrst battery life.
Similar ﬁndings were recently demonstrated in a
follow-up study from the MADIT-CRT (Multicenter
Automatic Deﬁbrillator Implantation Trial With
Cardiac Resynchronization Therapy) trial, in which
patients who were randomized in the initial study to
CRT-deﬁbrillator (CRT-D) and had paired echocar-
diograms at baseline and at 12 months (n ¼ 752) were
evaluated to assess the impact of improvement in LV
function on subsequent ICD therapies (12). All pa-
tients had LVEF #30% at the time of initial CRT-D
implant and ICDs were implanted for primary pre-
vention. At the 12-month follow-up, patients were
categorized into 3 groups: LVEF #35%; LVEF 36% to
50%; and LVEF >50% (“normalized” LVEF group).
During a mean follow-up of 2.2  0.8 years after the
initial CRT-D implant, the primary endpoint of
appropriate ICD therapy for VA $200 beats/min
occurred in only 1 of 55 patients (2%) with normali-
zation of LVEF; this event was treated without need
for ICD shock. There were no appropriate ICD shocks
among patients with normalized LVEF. In contrast,
the incidence of VA $200 beats/min was 7% among
those with LVEF 36% to 50% (n ¼ 594) and 18%
among those with LVEF #35% (n ¼ 103), supporting
the notion of an inverse relationship between LV
function and risk of SCD/VA. Two important aspects
of the MADIT-CRT substudy should be noted. First,
this cohort addressed improvement in LVEF and
reduction in ICD therapies during the ﬁrst battery life
and did not speciﬁcally address prognosis after GE.
Second, this study looked only at patients who had
recovery of LV function with CRT, which may be
mechanistically different than spontaneous
improvement in LVEF with medical therapy, as in the
study by Kini et al. (11).
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437In a recently published multicenter, prospective
cohort of 1,189 patients implanted with primary pre-
vention ICDs, Zhang et al. (13) reported on the out-
comes of 538 patients (45%) who underwent paired
assessments of LVEF at baseline and during follow-up
(mean time between ﬁrst and last LVEF measurement
of 4.9 years). Among the 538 patients, 215 (40%) had
improvement in LVEF (deﬁned as an absolute increase
>5%). Compared with those with unchanged LVEF,
the hazard ratio for all-cause mortality among those
with improved LVEF was 0.33 (95% CI: 0.18 to 0.59)
and for appropriate ICD shocks was 0.29 (95% CI:
0.11 to 0.78). There was a consistent relationship
noted between improving LVEF and decreased risk of
all-cause mortality and appropriate ICD shocks. Only 4
of 215 patients (1.9%) with improved LVEF experi-
enced an appropriate ICD shock. In aggregate, all 3 of
these studies are consistent in demonstrating a
signiﬁcantly lower risk of ICD therapies among those
with improvement in LVEF after initial implant and
reinforce the importance of LVEF in assessing future
risk of ICD therapies in those undergoing GE.
A few smaller studies have demonstrated contra-
dictory ﬁndings with regard to prognosis after GE
among those with recovered LVEF. In another Vet-
erans Affairs cohort, Naksuk et al. analyzed 97
consecutive patients undergoing GE following initial
implantation for primary prevention (14). From this
group, 25 patients (27%) had improved LVEF to >35%
and at least a 10% increase since the initial implant.
Mean LVEF among those in the improved LVEF group
was 49  8% versus 36  13% among those deemed
to have unchanged LVEF (p < 0.001). During a mean
follow-up of 6.2  2.2 years after GE, 9 patients (36%)
with improved LVEF had appropriate ICD therapies,
compared with 19 (29%) among those with unchanged
LVEF (p ¼ 0.51). On the basis of these ﬁndings, the
authors conclude that patients with improved LVEF
continue to exhibit a high rate of appropriate ICD
therapies after GE and that GE is, therefore, likely
indicated, even if LVEF has improved. However, it
is important to note that of the 25 patients in the
cohort with improved LVEF, 6 had appropriate ICD
therapies during the ﬁrst battery life and therefore
would likely be considered to have an ongoing ICD
indication. Only 3 patients in the improved LVEF
group had appropriate ICD therapies after GE without
having experienced appropriate ICD therapy during
the ﬁrst battery life. Additionally, most patients in
this study had multizone ICD programming with a
lowest rate cutoff for which a shock could be deliv-
ered of 171  14 beats/min in the improved LVEF
group and 165  16 beats/min in the unchanged LVEF
cohort. Although these programming practices mayhave been broadly consistent with the time period
during which these patients underwent GE (2006 to
2010), more contemporary data suggest that pro-
gramming primary prevention ICDs as a single zone
with high-rate cutoffs both reduces unnecessary ICD
shocks and improves clinical outcomes (15,16). It is
well-acknowledged that “appropriate” ICD shocks
overestimate the true incidence of aborted SCD in
deﬁbrillator recipients (17), and the use of multizone
programming with relatively low rate cutoffs in the
study by Naksuk et al. may have led to inclusion of
ICD shocks that were “appropriate,” but potentially
unnecessary and not life-saving. Last, in this study’s
unchanged LVEF cohort, the mean LVEF at the time
of GE was 36  13%, suggesting that a signiﬁcant
number of patients who were considered to have
unchanged LVEF had some improvement from the
time of initial implant, even if LVEF had not
increased by >10% compared with baseline (14).
Therefore, the lack of difference in ICD therapy event
rates between the 2 groups in this study may
have been a function of both groups exhibiting some
improvement in LVEF, albeit to a lesser extent among
those considered to have unchanged ejection frac-
tion. A more clear control group might have included
those with LVEF persistently #35% at the time of GE.
In a follow-up analysis from DEFINITE (De-
ﬁbrillators in Non-Ischemic Cardiomyopathy Treat-
ment Evaluation), Schliamser et al. (18) identiﬁed 187
patients from the overall study cohort of 449 (42%)
who had a follow-up assessment of LVEF between
90 and 730 days after enrollment (median 458 days).
Ninety-six patients had LVEF improvement >5%
from baseline, 79 had stable LVEF (#5% change from
baseline), and 12 had a decrease in LVEF >5% from
baseline. Those with improved LVEF had signiﬁcantly
better overall survival than those with stable or
decreased LV function, and the combined endpoint of
appropriate ICD shocks, SCD, and resuscitated cardiac
arrests also occurred signiﬁcantly less frequently in
the group with improved LVEF. However, in the
subgroup randomized to ICD implant, although the
incidence of appropriate ICD shocks was lower among
those with improved LVEF, the difference was not
signiﬁcant compared with the LVEF stable or
decreased groups. Although the lack of a signiﬁcant
difference in incidence of ICD shocks among those
with improved LVEF may have been due to limited
power in the subgroup with ICDs, the investigators
concluded that the presence of an ongoing risk for
ICD shocks should prompt routine GE, even among
those with improved LVEF.
Two additional factors should be noted with
regard to the relevance of changes in LVEF and
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438subsequent risk of VAs. First, it is well-acknowledged
that ﬁbrosis, electrical uncoupling, and other ultra-
structural changes play a role in the substrate that
gives rise to VAs in cardiomyopathy (19), and that this
substrate may persist, even among those with
improvement in LVEF, giving rise to a persistent
arrhythmic risk. However, the extent of this ongoing
risk and the way it should be incorporated into de-
cisions about GE among those with improved LVEF
remain unclear. Second, there is signiﬁcant interob-
server variability with regard to LVEF assessment,
particularly when echocardiography serves as the
diagnostic modality. Among patients enrolled in
PROSPECT (Predictors of Response to CRT Trial) (20),
more than 20% were found to have an LVEF >35%
when studies were rereviewed in a core laboratory,
suggesting that real-world variability in LVEF
assessment may confound the assessment of LV
function improvement in gauging arrhythmic risk
before GE.
PRESENCE OF APPROPRIATE ICD THERAPIES DURING
FIRST BATTERY LIFE. In addition to the status of LV
function at the time of GE (persistently impaired vs.
improved), another marker that has been evaluated
for risk-stratifying patients at the end of ICD battery
life is the presence or absence of appropriate ICD
therapies during the ﬁrst battery life. In a national
cohort of ICD patients enrolled in a remote moni-
toring system (Latitude, Boston Scientiﬁc Corp.,
Boston, Massachusetts), 24,203 patients underwent
GE for end of ﬁrst battery life, of whom two-thirds
(n ¼ 16,230) did not receive ICD shocks before
GE (uneventful ﬁrst battery life), whereas 7,973
experienced at least 1 shock with the ﬁrst generator
(21). At 3 years following GE, the cumulative inci-
dence of ICD shocks for VA with detection heart rate
>200 beats/min was signiﬁcantly lower among
those with an uneventful ﬁrst battery life (9.2% vs.
24.3%, p < 0.001) (Figure 1). Of note, given the large
number of patients included in this analysis, ICD
shocks were not adjudicated for being appropriate
versus inappropriate. The multicenter European
INSURE (Incidence Free Survival after ICD Replace-
ment) registry followed 510 patients after ﬁrst ICD GE,
of whom 265 (52%) had not received appropriate ICD
therapy with the ﬁrst battery life. At 3 years following
GE, the incidence of appropriate ICD therapies was
21.4% among those with uneventful ﬁrst battery life
compared with an incidence of 48.1% among
those who did receive appropriate therapy before
GE. Notably, more than 85% of patients in the
INSURE registry were initially implanted with ICDs
for secondary prevention (22), which may, in part,account for the higher 3-year event rate in this study
compared with the analysis by Merchant et al. (21).
In a single-center study of 154 primary prevention
ICD recipients undergoing GE for end of battery life,
Van Welsenes et al. (23) reported that 114 (74%) had
not received appropriate ICD therapy during the ﬁrst
generator. In this group, a ﬁrst appropriate ICD ther-
apy occurred in 14% of patients after GE following an
uneventful ﬁrst battery life. In a similar 2-center
study of 403 primary prevention ICD recipients un-
dergoing GE, 68% did not receive appropriate ICD
therapy during the ﬁrst generator (24); among these,
the 3-year incidence of appropriate therapy (shocks
and antitachycardia pacing) after GE was 13.7%.
These studies have all been generally consistent in
demonstrating that approximately two-thirds to
three-quarters of primary prevention ICD recipients
can be expected to reach end of ﬁrst battery life
without receiving appropriate ICD therapies. And
although the likelihood of ICD therapies after GE is
lower among those with an uneventful ﬁrst battery
life, the incidence of appropriate therapy after GE in
this cohort still appears to be on the order of 10% to
15% at 3 years (w5%/year). These ﬁndings are
consistent with the time dependence of appropriate
ICD therapies in primary prevention recipients re-
ported by Alsheikh-Ali et al. (25), demonstrating the
highest rate of therapy within the ﬁrst 2 years after
ICD implant (12% to 20%/year), followed by a lower,
but persistent incidence of ICD therapies from years
3 to 7 after implant (6% to 11%/year).
A signiﬁcant percentage of ICD recipients do not
survive to reach the end of ﬁrst battery life. Attrition of
the sickest patients with ICDs may conceivably lead to
lower than expected shock rates with second devices
among those who survive to GE, and may also account
for the apparently higher LVEF among those receiving
replacement devices compared with initial implants
(5). The extent to which attrition accounts for these
observations is unclear, but this remains an important
consideration when assessing outcomes after GE.
COMPETING RISKS OF ARRHYTHMIC VERSUS
NONARRHYTHMIC DEATH FOLLOWING GE. The
previously mentioned studies demonstrate that the
likelihood of receiving appropriate ICD therapy after
GE appears to be lower among those with improve-
ment in LV function and in those without appropriate
ICD therapies during the ﬁrst generator. However,
even among these patients, there continues to be a
measureable rate of appropriate ICD therapies after
GE. This rate is higher than the SCD/VA risk among
the general population, which has been estimated at
approximately 0.1%/year for men 50 years of age,
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439increasing tow0.8%/year for men 75 years of age (26).
The incidence of SCD among women in the general
population is generally lower than among men (26).
That the incidence of appropriate ICD therapies after
GE among those with improved LVEF and an un-
eventful ﬁrst battery life still appears to be higher
than the risk of SCD in the general population has
been used by some to suggest that the residual
arrhythmic risk in this population may justify routine
GE among all patients implanted with ICDs (14,18,27).
However, the notion that SCD/VA risk among those
with improved LVEF and uneventful ﬁrst battery life
is not zero or does not reach the low levels observed
in the overall population does not necessarily imply
that ongoing primary prevention ICD therapy is
justiﬁed or that GE should be performed routinely in
these patients. The beneﬁt of ICD therapy likely does
not depend speciﬁcally on the absolute risk of SCD/
VA, but, more importantly, on the relative balance
between competing risks of arrhythmic and non-
arrhythmic death. Although age should not be the
sole criterion for decisions about performing a GE, it
remains an important and clinically useful marker of
nonarrhythmic mortality risk. An analysis of 6,252
patients pooled from 13 clinical trials demonstrated
that, although the absolute risk of SCD increased per
decade of life from <50 to >80 years of age, the risk of
nonarrhythmic death increased to an even greater
degree, such that the ratio of SCD to all-cause mor-
tality decreased with increasing age (Figure 2) (28).
Given that patients undergoing GE are signiﬁcantly
older than those receiving new ICDs and have a
signiﬁcantly higher prevalence of comorbidities (5), it
is plausible that the risk of nonarrhythmic death may
be higher after GE than after initial ICD implant.
Additionally, among those undergoing GE who have
improved LVEF and have had an uneventful ﬁrst
battery life, the risk of SCD or appropriate ICD ther-
apies is likely lower than after the initial ICD implant
(25). Therefore, the relative balance between the risks
of arrhythmic and nonarrhythmic death may be suf-
ﬁciently altered after GE such that ongoing ICD
therapy may no longer be beneﬁcial. An analysis from
the National Cardiovascular Data Registry provides
some evidence to support this notion by demon-
strating that all-cause mortality at 1 and 3 years after
GE is signiﬁcantly higher than at the same time points
following initial ICD implant: 9.9% versus 9.4% at
1 year and 27.4% versus 23.5% at 3 years (6). This
difference in survival remained signiﬁcant, even after
propensity-score matching of patients after GE and
after initial ICD implant.
Although there is a paucity of data on predictors of
mode of death after GE, several attempts have beenmade to predict the risk of speciﬁc modes of death
after initial ICD implant. The MADIT-II investigators
developed a risk model to predict all-cause mortality
at 2 years after ICD implant and identiﬁed 5 signiﬁ-
cant markers of total mortality: New York Heart As-
sociation functional class >II; age >70 years; blood
urea nitrogen >26 mg/dl; QRS duration >120 ms; and
history of atrial ﬁbrillation (AF) (29). In this analysis,
compared with patients in the control arm of the
MADIT-II study, ICD therapy was associated with a
signiﬁcant reduction in all-cause mortality among
those with either 1 or 2 of the 5 risk markers, whereas
no signiﬁcant beneﬁt of ICD therapy was seen among
those with $3 risk markers, presumably because the
competing risk of nonarrhythmic death was too high
in this subgroup, thus negating any potential beneﬁt.
In a similar substudy from the MUSTT (Multicenter
Unsustained Tachycardia Trial), the investigators
identiﬁed predictors of total and arrhythmic mortal-
ity and found that both increasing age and history of
AF were signiﬁcant predictors of all-cause mortality,
but not of arrhythmic death (30).
In aggregate, these data suggest that due in large
part to older age and a higher prevalence of comor-
bidities, including AF, the risk of nonarrhythmic
death likely increases to a greater extent than the risk
of arrhythmic death following GE. It remains to be
determined whether the ratio of arrhythmic to non-
arrhythmic death after GE among those with
improved LVEF and uneventful ﬁrst battery life is
sufﬁciently low that ongoing primary prevention ICD
therapy is no longer beneﬁcial. However, this type of
analysis, assessing both arrhythmic and non-
arrhythmic risks of death, is likely to provide a more
clinically relevant determination of whether GE is
beneﬁcial rather than focusing solely on the absolute
risk of SCD/VA.
More broadly, for many patients with ICDs, both
cardiac (i.e., heart failure burden) and noncardiac
comorbidities may progress during the time between
initial ICD implant and GE. In a similar vein, with
advancing age, the development of frailty, deﬁned as
loss of physiological reserve and vulnerability to
stressors that may span multiple physical, cognitive,
and functional domains, may have important impli-
cations for the decision to perform a GE (31). Although
the guidelines suggest that candidates for ICD im-
plantation and, by extension, for GE, should have a
“reasonable expectation of survival with an accept-
able functional status for at least 1 year” (1), making
such determinations for individuals with heart failure
and other signiﬁcant comorbidities can be chal-
lenging. Numerous risk models exist for predicting
mortality in patients with advanced heart failure;
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440however, most have modest accuracy, and the speciﬁc
trajectory for an individual patient is often unclear
(32). Even in the absence of high-quality tools to assess
prognosis and functional status, at least a qualitative2 Changing Ratio of Sudden Deaths to All-Cause Mortality With
ing Age
<50 51-60 61-70 71-80 >80
sudden death all-cause death
Age (Years)
rate of sudden death and all-cause death stratiﬁed by age in 6,252
. Although the rates of both sudden and all-cause mortality increase
, the rate of increase in all-cause mortality is greater, resulting in a
roportion of sudden deaths. Reproduced with permission from
t al. (28).assessment of progression of cardiac and noncardiac
comorbidities and a discussion of how they may
have affected patient preferences regarding ongoing
ICD therapy, should be undertaken before GE.
RISKS ASSOCIATED WITH GE
ICD GE is often viewed as a straightforward proce-
dure, yet published reports suggest that it is asso-
ciated with important complications, most notably
infection. The multicenter REPLACE (Implantable
Cardiac Pulse Generator Replacement) registry (7)
had a 4.9% major complication rate associated
with ICD GE, with an even higher event rate noted
among those with CRT-deﬁbrillators. The rate of
device infection associated with GE in the REPLACE
registry was 1.4% for ICDs and 2.3% for CRT-D
generators (33). The risk of device infection associ-
ated with GE is roughly 2-fold higher than after
initial ICD implant (34), and the occurrence of major
complications associated with ICD generator
replacement has been associated with a nearly 10-
fold increased risk of all-cause mortality at 45 days
post-procedure compared with those without major
complications (8).
These data reinforce the notion that ICD GE is
associated with a signiﬁcant rate of major complica-
tions that may increase mortality post-procedure.
Therefore, to minimize exposure to GE-related
CENTRAL ILLUSTRATION Paradigm for Weighing the Changes in Risk-Beneﬁt Ratio Between the Time of Initial Implantable
Cardioverter-Deﬁbrillator Implant and Generator Exchange
 Initial implantable cardioverter-defibrillator (ICD) implant  ICD generator exchange after initial battery life ends
Reduced
total mortality
Lower risk of 
implant-associated 
infection
Greater focus on 
quantity of life
Opportunity to replace 
cardiac resynchronization 
therapy (CRT)-defibrillator 
with CRT-pacemaker
Opportunity to gather 
adjunctive heart failure 
management data
Increased risk of 
non-arrhythmic death
Increased risk of implant-
associated infection
Reduced risk of 
arrhythmic death
Potential for painful ICD 
shocks/reduced quality of life
PROS
CONS
CONSPROS
Ability to monitor for 
atrial arrhythmias
Merchant, F.M. et al. J Am Coll Cardiol. 2016; 67(4):435–44.
Whereas clinical trial data exist to support decision making at the time of initial ICD implant, a lack of high-quality clinical evidence results in much greater uncertainty at
the time of generator exchange.
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441complications, the impetus to identify patients who
are themost or least likely to beneﬁt fromGE should be
even stronger.
OTHER CONSIDERATIONS ON GE
Although prevention of SCD/VA is usually the pre-
dominant consideration in making a decision to
initially implant an ICD and to perform a GE, other
factors may also be taken into consideration when
making decisions at the end of battery life. For
instance, among patients with atrial leads, device-
detected subclinical AF is associated with an
increased risk of stroke or systemic embolism (35) and
may prompt anticoagulation therapy among those
without clinically evident AF. The ability to monitor
for incidence and burden of atrial arrhythmias may
represent a beneﬁt to GE unrelated to SCD/VA. Simi-
larly, some devices are also capable of providing
adjunctive data for management of heart failure, such
as thoracic impedance monitoring, heart rate de-
rivatives, and hemodynamic pressure sensors (36),
which may be beneﬁcial in certain patient subgroups.
Last, an important consideration among CRT-D
recipients who have improvement in LVEF is the
potential for replacement of the generator with a
CRT-pacemaker (CRT-P) (12). Replacement with aCRT-P generator may also be a good option for pa-
tients in whom ICD therapy is no longer consistent
with goals of care, but who may still receive symp-
tomatic beneﬁt from CRT. In the COMPANION (Com-
parison of Medical Therapy, Pacing, and Deﬁbrillation
in Heart Failure) trial, compared with pharmacolog-
ical therapy alone, CRT-P reduced the incidence of
the primary endpoint (death or all-cause hospitaliza-
tion) by 34%, and CRT-D reduced the incidence by
40%, suggesting that CRT provides robust beneﬁt,
even in the absence of deﬁbrillator therapy (37).
PERSPECTIVES ON ICD THERAPY AT
END OF LIFE
In many cases, ICD therapy is viewed as a lifelong
commitment. Guidelines exist on deactivation of ICD
therapy and clearly state that discussions about the
potential for withdrawal of ICD therapy should begin
before device implant and continue to occur at other
sentinel events during a patient’s course (e.g., time
of ICD shocks, progression of cardiac and noncardiac
disease, initiation of an advanced directive) (38).
However, in practice, discussions regarding with-
drawal of ICD therapy are often not held until
patients reach a more critical state in disease pro-
gression, often when palliative or hospice-related
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442care is being considered. For many community-
dwelling patients with ICDs, the failure to proac-
tively address goals of care with regard to ICD therapy
may result in the delivery of painful ICD shocks
immediately before death. In a Swedish cohort of
explanted ICDs after death, 35% of patients received
ICD shocks within the last hour of life, but in only 13%
of cases was death felt to be primarily from an
arrhythmic cause, whereas death was due to pro-
gressive heart failure or noncardiac causes in the vast
majority (39), suggesting that the delivery of shocks
in this setting was unlikely to change the ultimate
outcome. Additionally, more than one-half of pa-
tients in this cohort had an advanced directive
including a do-not-resuscitate order, but nearly two-
thirds of these patients still had tachytherapies
enabled within 24 h of death, and nearly one-half
received ICD shocks within the ﬁnal 24 h of life. These
data suggest that a signiﬁcant opportunity exists to
more closely align patients’ desires regarding care at
the end of life with ICD programming and with the
decision to perform GE, with the recognition that, for
many patients, the end-of-life period is foreseeable
months in advance because of advancing noncardiac
conditions, such as such as dementia, progressive
lung disease, cancer, or frailty/debility syndromes.
Several studies have suggested that only one-half
to two-thirds of ICD recipients are aware that deac-
tivation is an option, but the overwhelming majority
believe that patients should be informed of the option
to deactivate ICD therapy, ideally before initial im-
plantation or at the time of end of battery life (40,41).
Many patients are also unclear about the implications
of deactivation; speciﬁcally, that this does not
necessarily mean shorter lifespan or decreased qual-
ity of life. In a survey of 294 ICD recipients, the only
multivariate predictor of a favorable attitude toward
ICD deactivation was the desire to die “a worthy
death,” deﬁned, in part, by the “avoidance of shocks
during dying” (40). However, data on the preferences
of ICD recipients regarding device deactivation are
still relatively limited, and better tools are needed to
help providers gauge patient preferences with regard
to ICD management. Educational initiatives would
also be useful to help providers traverse the conver-
sation about end-of-life goals and to support patients
and families, particularly when concerns exist
regarding quantity and quality of life. The end of ICD
battery life represents an opportune time for a
different form of risk stratiﬁcation, focusing not on
reductions in mortality or complications associated
with generator exchange, but more broadly on patient
goals of care and the potential to avoid painful ICD
shocks at the end of life.OPPORTUNITIES FOR IMPROVED DECISION
MAKING AT END OF ICD BATTERY LIFE
Whereas a relatively robust body of literature exists
to identify which patients are most likely to beneﬁt
from primary prevention ICD implantation, there is a
notable paucity of data to identify which patients are
most likely to beneﬁt from ICD generator exchange.
Available data suggest that the proﬁles of patients
undergoing GE are signiﬁcantly different from those
undergoing initial ICD implant and, as such, the
relative risk of arrhythmic versus nonarrhythmic
death following GE may differ from that following
initial ICD implant. There is a critical need for better
evidence to support informed decision-making at the
time of ICD battery depletion:
 Multicenter, prospective registries are necessary to
provide a better assessment of presumed causes of
death after GE (arrhythmic vs. nonarrhythmic),
along with better estimates of the incidence of ICD
shocks immediately before death.
 Ultimately, randomized trials are likely needed to
clearly deﬁne which patients are most or least likely
to beneﬁt from ICD GE. The most obvious groups to
begin with would include those with improved
LVEF since the time of initial ICD implant and those
with uneventfulﬁrst ICD battery life because both of
these markers have consistently been associated
with a lower risk of appropriate ICD therapies after
GE. Because the potential beneﬁt to ICD therapy
depends on a balance between arrhythmic and
nonarrhythmic risks of death, it seems likely that
only randomized trials will be capable of deﬁning
whether that balance continues to favor ICD therapy
after GE. However, given the lower rates of appro-
priate ICD therapies after GE among those with
improved LVEF and uneventful ﬁrst battery life (11),
designing adequately powered trials would likely
require large numbers of patients and extended
duration of follow-up to accrue enough events.
Performing such studies is costly and logistically
challenging. The use of registry-based clinical trials,
leveraging electronic health records and other novel
approaches to trial design, may provide alternatives
to gathering high-quality clinical data (42).
 Additional data are needed on patient perspectives
regarding continued ICD therapy and, in particular,
how those perspectives may change over time after
initial ICD implant.
 Better tools are needed to help providers commu-
nicate the risks and beneﬁts of ongoing ICD ther-
apy to patients and how ICD therapy may affect
goals of care at the end of life.
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443Given the large number of ICDs implanted annually
and the high likelihood of patients surviving through
their initial ICD generator, these areas of investigation
would allow for a more systematic approach and
facilitatemore robust decision-making by patients and
providers at the time of ICD GE (Central Illustration).
Until more data are available, it is also important for
providers to communicate the uncertainty aboutdecision making at the time of GE to patients and to
engage patients in the decision-making process.
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